Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase
- PMID: 15855480
- PMCID: PMC1087622
- DOI: 10.1128/AAC.49.5.1671-1678.2005
Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase
Figures



Similar articles
-
Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.Antivir Ther. 2001;6 Suppl 3:25-44. Antivir Ther. 2001. PMID: 11678471 Review.
-
Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1.J Antimicrob Chemother. 2004 Jan;53(1):53-7. doi: 10.1093/jac/dkh009. Epub 2003 Nov 25. J Antimicrob Chemother. 2004. PMID: 14645322 Review.
-
A rational approach to the selection and sequencing of nucleoside/nucleotide analogues: a new paradigm.Antivir Ther. 2001;6 Suppl 3:45-54. Antivir Ther. 2001. PMID: 11678472 Review.
-
Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.Antimicrob Agents Chemother. 2006 Aug;50(8):2772-81. doi: 10.1128/AAC.00127-06. Antimicrob Agents Chemother. 2006. PMID: 16870771 Free PMC article.
-
Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.J Infect Dis. 1999 Aug;180(2):568-71. doi: 10.1086/314909. J Infect Dis. 1999. PMID: 10395885 No abstract available.
Cited by
-
Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.Antimicrob Agents Chemother. 2007 Jan;51(1):48-53. doi: 10.1128/AAC.00683-06. Epub 2006 Nov 6. Antimicrob Agents Chemother. 2007. PMID: 17088490 Free PMC article.
-
Drug resistance mutation profiles of the drug-naïve and first-line regimen-treated HIV-1-infected population of Suzhou, China.Virol Sin. 2017 Aug;32(4):271-279. doi: 10.1007/s12250-017-4002-y. Epub 2017 Aug 7. Virol Sin. 2017. PMID: 28795354 Free PMC article.
-
Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape.BMC Bioinformatics. 2010 Aug 3;11:409. doi: 10.1186/1471-2105-11-409. BMC Bioinformatics. 2010. PMID: 20682040 Free PMC article.
-
Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.Antimicrob Agents Chemother. 2007 Nov;51(11):3861-9. doi: 10.1128/AAC.00646-07. Epub 2007 Aug 27. Antimicrob Agents Chemother. 2007. PMID: 17724152 Free PMC article.
-
Determination of Phenotypic Resistance Cutoffs From Routine Clinical Data.J Acquir Immune Defic Syndr. 2017 Apr 15;74(5):e129-e137. doi: 10.1097/QAI.0000000000001198. J Acquir Immune Defic Syndr. 2017. PMID: 27787339 Free PMC article.
References
-
- Anonymous. 29 October 2004. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. http://aidsinfo.nih.gov/guidelines/default_db2.asp?id=50. Accessed 26 November 2004. U.S. Department of Health and Human Services, Washington, D.C.
-
- Bazmi, H. Z., J. L. Hammond, S. C. Cavalcanti, C. K. Chu, R. F. Schinazi, and J. W. Mellors. 2000. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (−)-β-d-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 44:1783-1788. - PMC - PubMed
-
- British HIV Association. 2003. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 4(Suppl. 1):1-41. - PubMed
-
- Brun-Vezinet, F., D. Descamps, A. Ruffault, B. Masquelier, V. Calvez, G. Peytavin, F. Telles, L. Morand-Joubert, J. L. Meynard, M. Vray, and D. Costagliola. 2003. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 17:1795-1802. - PubMed
-
- Clumeck, N., F. Goebel, W. Rozenbaum, J. Gerstoft, S. Staszewski, J. Montaner, M. Johnson, B. Gazzard, C. Stone, R. Athisegaran, and S. Moore. 2001. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 15:1517-1526. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical